Last reviewed · How we verify
VBI-2901a
At a glance
| Generic name | VBI-2901a |
|---|---|
| Sponsor | VBI Vaccines Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VBI-2901a CI brief — competitive landscape report
- VBI-2901a updates RSS · CI watch RSS
- VBI Vaccines Inc. portfolio CI